Y-90 Radioembolization, also known as Transarterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT), is a minimally invasive liver-directed treatment that delivers targeted radiation to tumors using tiny microspheres containing Yttrium-90. The microspheres are introduced through the hepatic artery supplying the tumor, allowing radiation to be concentrated within the affected area.
Who May Benefit from Y-90 Radioembolization?
Y-90 therapy may be considered for selected patients with liver cancer, including hepatocellular carcinoma and certain cancers that have spread to the liver. Suitability depends on factors such as tumor location and size, liver function, overall health, blood-vessel anatomy, and previous treatments. A specialist evaluation and imaging are essential before treatment.
How Does the Treatment Work?
Before treatment, doctors perform detailed imaging and vascular mapping to plan how the microspheres will reach the tumor safely. During the procedure, a thin catheter is guided into the liver artery, and Y-90 microspheres are carefully delivered to the tumor-feeding vessels. Follow-up imaging and blood tests help assess treatment response and liver function.